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The cancer killing efficacy of standard chemotherapeutic agents such as cisplatin (CDDP) is limited by their side effects to
normal tissues. Therefore, research efforts optimizing the safety and efficacy of those agents are clinically relevant. We did
screen for agents that specifically protect normal human mesothelial cells against CDDP without reducing the cancer cell
killing efficacy. Lovastatin was identified from the screen. Lovastatin at a pharmacologically relevant concentration strongly
arrested the proliferation of normal cells, whereas cancer cells were less affected. CDDP-induced DNA damage response was
not activated and normal cells showed enhanced tolerance to CDDP when normal cells were treated with the combination
of CDDP and lovastatin. We demonstrate that interfering with protein geranylgeranylation is involved in the lovastatin-
mediated CDDP protective effect in normal cells. In contrast to normal cells, in cancer cells lovastatin did not change the
CDDP-induced response, and cancer cells were not protected by lovastatin. Furthermore, lovastatin at the pharmacological
relevant concentration per se induced DNA damage, oxidative stress and autophagy in cancer cells but not in normal
mesothelial cells. Therefore, our data suggest that lovastatin has a potential to improve the therapeutic index of cisplatin-
based therapy.
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Introduction
Cisplatin (CDDP) is a standard chemotherapeutic agent for the
treatment of various solid tumors. However, side effects to normal
tissues result in limited tolerance in patients [1]. Thus, therapeutic
strategies circumventing the toxic side effects of CDDP would be
welcome and might improve the therapeutic outcome.
Loss or weakened cell cycle checkpoints are among the most
universal alterations in cancer cells, resulting in reduced sensitivity
to proliferation-inhibitory signaling that normally initiate a variety
of responses including proliferation arrest, activation of self-
protection mechanisms against stresses, differentiation, or cell
death [2]. Under certain proliferation-limiting conditions, normal
cells arrest their replication and thereby may be protected from the
toxicity of proliferation-dependent agents, e.g. the DNA-damaging
agents. However, cancer cells, due to their reduced sensitivity to
proliferation-inhibitory signaling, cannot properly arrest their cell
cycle and are therefore selectively killed under these conditions [3–
6].
Our aim was to find agents which could protect normal cells
against cisplatin cytotoxicity and at the same time allow killing
cancer cells. Therefore, we set up a two-step screen: first, we
screened a series of compounds for differential effects on the
proliferation of normal mesothelial versus mesothelioma cells;
second, combined actions of CDDP with those differentiating
agents were tested in normal cells to identify agents which make
normal cells tolerant to CDDP cytotoxicity while allowing cancer
cells killing.
Lovastatin was identified from our screen. As a cholesterol-
lowering drug, lovastatin acts by inhibiting HMG-CoA reductase,
the rate-limiting enzyme of the cholesterol biosynthesis pathway
[7]. Blocking the cholesterol synthesis pathway also results in the
depletion of isoprenoid moieties thereby interfering with protein
isoprenylation, which is a crucial regulatory step in many
biological procedures [7]. Therefore, beyond the cholesterol-
lowering function, lovastatin also performs pleiotropic biological
roles in the control of cell proliferation, apoptosis, survival,
differentiation, migration and cellular vesicle trafficking [7–9].
Our data show that lovastatin has a potential to increase the
therapeutic index of CDDP.
Materials and Methods
Cell Cultures and Reagents
Normal human mesothelial primary cells and cancer cells were
cultured in M199 (Invitrogen)/MCDB105 (Sigma) (1:1) mixed
medium supplemented with 15% FCS, 10 ng/ml EGF, and
0.4 mg/ml hydrocortisone as described [10]. The human meso-
thelioma cell line ZL55 [11] and the primary normal cell culture
SDM104 [12] were generated in our laboratory. The breast
cancer cell line MCF-7 [13] and the human lung adenocarcinoma
cell line A549 [14] were purchased from American Type Culture
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Corporation (Manassas, VA). The primary normal cell culture
LP9 [15] was from Dr. James Rheinwald’s laboratory. The
primary normal cell culture SDM85 was established from a
normal pleural tissue received from a patient undergoing cancer
unrelated thoracic surgery. The study was approved by the Zu¨rich
University Hospital ethic committee and a written informed
consent was obtained from the patient. All cell lines used in this
study were authenticated by fingerprinting (Microsynth, Balgach,
Switzerland). Lovastatin (Alexis Biochemicals) was converted into
the active acid form as described [16] and used at a concentration
of 2 mM in most experiments. Cisplatin (0.5 mg/ml saline
solution) was purchased from Ebewe Pharma; mevalonate, GGPP
and FTI-277 from Sigma; GGTI-298 from Calbiochem. Anti-
ATM-Ser1981 (Epitomics), anti-ATM (2C1) (Gene Tex), anti-c-
H2AX (Ser139) (Millipore), anti-LC3B (Abcam), anti-phospho-
p53 (Ser15) (Cell Signaling Technology), anti-p53, anti-b-Actin,
anti-Heme Oxygenase 1 (HO 1), anti-p21, anti-H-Ras, anti-
Rap1a and anti-vinculin (Santa Cruz) were used according to the
Figure 1. Lovastatin differentially affected the cell proliferation of normal versus cancer cells in vitro. The experimental protocol for the
investigation of agents protecting normal cells against CDDP cytotoxicity is shown in (A). Cell cycle profiles of normal SDM104 (B) and (C), and ZL55
cancer cells (D) and (E) of control without treatment (B) and (D), or 24 hours treatment with 2 mM lovastatin (C) and (E) are shown (n= 3). Cells were
exposed to 10 mM BrdU for one hour before harvesting for FACS analysis.
doi:10.1371/journal.pone.0045354.g001
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product instructions. For western blot detection of ATM, protein
extracts were run in 5% SDS-polyacrylamide gel while for the rest
13.5% SDS-polyacrylamide gel was used.
Cell Proliferation and Cell Cycle Analysis
MTT cell proliferation assay was performed as described [17].
For the compound screen, the analysis of the cell cycle distribution
was done as following: cells were harvested after 24-hour
treatment with different agents, washed with PBS and fixed in
70% ethanol overnight at 4uC. After propidium iodide (PI) (Sigma)
staining, flow cytometry (FACS) analysis was performed with
FACSCalibur (FACScan, BD Biosciences) and data was analyzed
with ModFit LT 3.2.1 software. For the detailed FACS analysis of
lovastatin-treated cells, cells were exposed to 10 mM BrdU for one
hour before harvesting. Cells were harvested after 24 hour
lovastatin-treatment and fixed in 70% ethanol. After anti-BrdU
antibody (BD Biosciences)/Secondary Alexa488-conjugated goat-
anti-mouse (Invitrogen) and PI staining, FACS analysis was
performed with FACSCalibur and data was analyzed with Summit
v4.3 software. The statistical significance was performed with two-
tailed t-Test.
Results
Lovastatin Differentially Affected the Cell Proliferation of
Normal versus Cancer Cells and Specifically Protected
Normal Cells from CDDP Cytotoxicity in vitro
The screen for agents which could protect normal cells against
cisplatin-induced cytotoxicity was performed in two steps. In the
first step, we studied the literature and selected candidate agents
from which we found indications that they might differentially
affect proliferation of normal versus cancer cells. Cell cycle profiles
of normal human mesothelial SDM104 cells and human
mesothelioma ZL55 cells were analyzed 24 hours after exposure
to commercially available agents known to interfere with cell
proliferation. Some of the agents showing different effects on the
cell cycle distribution in normal versus cancer cells are listed
(Table 1). In the second step, we tested which of the selected agents
protected normal cells from CDDP (Figure 1A). Lovastatin, an
FDA-approved cholesterol-lowering drug, was identified in the
second step.
Lovastatin at the pharmacological relevant concentration [18]
of 2 mM in normal cells reduced more than 98% of the S-phase
cells and about 14% of the G2/M cells while there was about
47.8% increases of G0/G1 cells (Figure 1C), as compared to
untreated control (Figure 1B). In contrast, in cancer cells there
were still about 20% of the S-phase cells remaining and both G0/
G1 cells and G2/M cells were increased 58% and 77.7%,
respectively (Figure 1E) after lovastatin-treatment, compared to
untreated control (Figure 1D). Thus, lovastatin showed different
effects on the proliferation of normal cells versus cancer cells.
Consistent with changes observed in cell cycle, treatment with
lovastatin alone, significantly suppressed the proliferation of
normal (P,1.061026), and cancer ZL55 (P,0.001) and MCF-7
(P,0.001) cells, compared to untreated controls (Figure 2A).
The number of normal SDM104 cells after the combined
treatment of CDDP and lovastatin was 3.8 times higher compared
to the cell number observed after treatment with CDDP alone.
This protective effect against CDDP toxicity was also observed in
two additional normal primary cultures SDM85 and LP9
(Figure 2A). The lovastatin-mediated protective effect seemed
specific for normal cells, since none of the tested cancer cell lines,
human mesothelioma ZL55, human breast cancer MCF-7 and
human lung adenocarcinoma A549, was protected (Figure 2A).
A lovastatin dose response for protective effect against CDDP
cytotoxicity was performed with SDM104 cells. Lovastatin dose-
dependently reduced cell growth, however, the maximal protective
effect was observed already at 2 mM (Figure 2B). Thus, 2 mM
lovastatin concentration was used in most of our experiments.
Because lovastatin-mediated protection of normal cells was linked
to cell cycle arrest, CDDP-protective effects was visible only at
high CDDP concentration (10–20 mM) where reduction in cell
number due to cytotoxicity was higher than lovastatin-induced cell
number reduction due to proliferation arrest (Figure 2C).
Blocking the Cholesterol Biosynthetic Pathway but not
Ubiquinone Synthesis is Required for the Lovastatin-
mediated Protection of Normal Cells from Cisplatin
Toxicity
As a lipid lowering agent, lovastatin acts to inhibit HMG-CoA
reductase, the rate-limiting enzyme of cholesterol biosynthetic
pathway [7] (Figure 3A). We examined whether blocking the
cholesterol biosynthetic pathway is required for the lovastatin-
mediated protection of normal cells against CDDP by testing the
effects of mevalonate, which is the immediate product of HMG-
CoA reductase-catalyzed reaction in the cholesterol biosynthetic
pathway [7] (Figure 3A). Addition of mevalonate completely
reversed the inhibitory effects of lovastatin on cell proliferation.
Lovastatin did not protect normal cells against CDDP in the
presence of mevalonate (Figure 3B), indicating that lovastatin
protects normal cells by blocking the cholesterol biosynthetic
pathway. The addition of ubiquinone (coenzyme Q10) in normal
cells did not change either the inhibitory effect of lovastatin on cell
proliferation or the protection from CDDP (Figure 3C) indicating
Table 1. Different effects of agents on the cell cycle distribution of normal versus cancer cells.
Agents ZL55 SDM104
Hsp90 inhibitor 17-AAG (0.25mM) G1 and G2/M arrest G2/M arrest, still S phase cells
EGFR inhibitor AG1478 (20mM) G1 arrest No response
Akt Inhibitor II (20mM) G1 arrest No response
PKC inhibitor GF109203X (10mM) G1 arrest No response
Lovastatin (2mM) G1 delay, still S phase cells G1 and G2/M arrest
Nocodazole (50nM) G2 arrest and cell death G1 and G2/M arrest and cell death
Pemetrexed (10nM) G1 and S arrest No response
Kinase inhibitor UCN-01 (25nM) G1 arrest No response
doi:10.1371/journal.pone.0045354.t001
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Figure 2. Lovastatin specifically protecting normal but not
cancer cells from CDDP toxicity in vitro. Results of MTT assays with
primarily cultured normal cells (SDM104, SDM85 and LP9) and cancer
cells (ZL55, A549 and MCF-7) after treatments with CDDP alone,
lovastatin (2 mM) alone, or both together are shown in (A) (n = 6; * for
P,3.061025). In (B), MTT assays were performed after SDM104 cells
were treated with different concentrations of lovastatin alone, or
lovastatin together with 20 mM CDDP (n = 6; * for P,0.002; ** for
P,3.061025); L0.5, L1, L2 and L4 stand for 0.5 mM, 1 mM, 2 mM and 4mM
lovastatin, respectively; and C for CDDP. In (C), MTT assays were
performed after SDM104 cells were treated with 2 mM lovastatin alone,
CDDP of different concentrations alone, or both together (n = 6; * for
P,0.02; ** for P,1.061025); C5, C10, and C20 stand for 5 mM, 10 mM
and 20 mM CDDP, respectively.
doi:10.1371/journal.pone.0045354.g002
Figure 3. Blocking the cholesterol biosynthetic pathway is
involved in the lovastatin-mediated protection of normal cells.
A scheme for the cholesterol biosynthetic pathway is shown in (A). In
(B) and (C), 20 mM CDDP were added after 8 hours pre-incubation with
2 mM lovastatin in the presence or absence of 200 mMmevalonate (B) or
100 mM Q10 (C), then cells were cultured for another 16 hours in the
presence of CDDP and the other agents together (n = 6; * for
P,7.061027). MTT assays were performed after the treatments ended
and cells were cultured again in fresh medium for 24 hours. In (B) and
(C), ‘‘L’’ stands for lovastatin, ‘‘M’’ for mevalonate.
doi:10.1371/journal.pone.0045354.g003
Effects of Lovastatin in Normal and Cancer Cells
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the interference with the ubiquinone synthesis is not involved in
the observed protection of normal cells.
Protection of Normal Cells from Cisplatin Toxicity is
Mediated through Lovastatin-Induced Interference of
Protein Geranylgeranylation
Lovastatin interferes with protein isoprenylation (including
farnesylation and geranylgeranylation) through depleting the
isoprenoid donors farnesyl pyrophosphate (FPP) and geranylger-
anyl pyrophosphate (GGPP) [7] (Figure 3A, and 4A and 4C).
Farnesyltransferase inhibitor (FTI-277) specifically inhibits the
farnesylation of small G proteins, e.g., the farnesylation of H-Ras
(Figure 4A) but not protein geranylgeranylation, e.g., the
geranylgeranylation of Rap1a in normal SDM104 cells
(Figure 4C). FTI-277 showed much weaker proliferation inhibitory
effect on normal cells (Figure 4B) than lovastatin (Figure 3B), and
its CDDP-protective effect to normal cells (Figure 4B) was also
weaker than lovastatin (Figure 3B). However, the specific
inhibition of geranylgeranylation by a geranylgeranyltransferase-
I inhibitor (GGTI-298) (Figure 4C), which did not affect
farnesylation (Figure 4A), strongly inhibited the proliferation of
normal cells and protected them from cisplatin toxicity (Figure 4B)
similar to lovastatin (Figure 3B). Consistent with these observa-
tions, the cell proliferation-inhibitory effects and the CDDP
protective effect of lovastatin for normal cells were dramatically
suppressed by the addition of GGPP (Figure 4D), which reversed
the lovastatin-mediated inhibition of geranylgeranylation
(Figure 4C) but not farnesylation (Figure 4A). Thus, our data
demonstrates that lovastatin-mediated protection of normal cells
from CDDP toxicity is mainly due to the GGPP depletion-induced
inhibition of geranylgeranylation.
Lovastatin Prevents the Activation of CDDP-induced DNA
Damage Responses in Normal Cells but Induces DNA
Damage Responses in Cancer Cells
To further explore the mechanism of lovastatin-mediated
differential effects on normal versus cancer cells, the responses of
normal versus cancer cells were examined in more details. As
expected, CDDP activated the DNA damage responses [19–22] in
normal cells: the phosphorylation of ATM, the consequent
accumulation of the DNA damage marker phospho histone
H2AX on Serine 139 (c-H2AX), the phosphorylation and
accumulation of p53, and the accumulation the cell cycle inhibitor
p21 (Figure 5A). However, except for p21 upregulation, DNA
damage response was not detected when cells were treated with
lovastatin 8 hours prior and during CDDP treatment (Figure 5A),
indicating that lovastatin, by arresting cell growth, suppressed the
DNA damage response and protected normal cells from CDDP-
induced cytotoxicity. Lovastatin-induced up-regulation of p21 was
likely through a p53-independent pathway since no detectable
activation of p53 was observed in normal cells treated with
lovastatin alone (Figure 5A).
Figure 4. Protection of normal cells from cisplatin toxicity is through interference of protein geranylgeranylation. Results of Western
blot with anti-H-Ras antibody (A) and anti-Rap1a antibody (C) are shown. Protein extracts were made right after normal SDM104 cells were treated
with different compounds for 16 hours. b-Actin used as loading control for Western. In (B), 20 mM CDDP were added after 8 hours pre-incubation
with 10 mM GGTI-298 (GGTI) or 10 mM FTI-277 (FTI), and then cells were cultured for another 16 hours in the presence of CDDP and the inhibitors
together (n = 6; * for P,3.061024; ** for P,2.061026). In (D), 20 mM CDDP were added after 8 hours pre-incubation with 2 mM lovastatin in the
presence or absence of 10 mM GGPP, and then cells were cultured for another 16 hours in the presence of CDDP and the compounds together (n = 6;
** for P,2.061026). In (B) and (D), MTT assays were performed after the treatments ended and cells were cultured again in fresh medium for 24
hours. ‘‘L’’ stands for lovastatin.
doi:10.1371/journal.pone.0045354.g004
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In cancer cells, in contrast to normal cells, the CDDP-induced
DNA damage response including the activation of ATM,
accumulation of c-H2AX and p53 were not changed in the
combined treatment with lovastatin (Figure 5B). Importantly,
while lovastatin alone did not induce further response except p21
upregulation in normal cells (Figure 5A), it resulted in increased
levels of P-ATM, p53 and c-H2AX in cancer cells (Figure 5B)
indicating that lovastatin at the pharmacological relevant concen-
tration of 2 mM per se induces DNA damage in cancer cells.
Lovastatin Induces Autophagy and Oxidative Stress in
Cancer but not Normal Cells
Consistent with other studies reporting lovastatin-induced
autophagy [23–25], we observed that lovastatin triggered the up-
regulation of the autophagy marker LC3B-II [26] in cancer cells
Figure 5. Lovastatin inhibits the activation of CDDP-induced DNA damage responses in normal cells but induces DNA damage
responses in cancer cells. Western blot analysis of components in DNA-damage response in SDM104 normal cells (A) and cancer cells (B) after
treatment with CDDP in the presence or absence of lovastatin are shown. Vinculin and b-actin were used as loading control. For CDDP treatment,
cells were cultured in the presence of 8 mM CDDP for 16 hours; for lovastatin, cells were cultured in the presence of 2 mM lovastatin for 24 hours; for
the combination of CDDP and lovastatin, 8 mM CDDP were added 8 hours after 2 mM lovastatin pre-incubation, then cells were cultured for another
16 hours in the presence of CDDP and lovastatin together.
doi:10.1371/journal.pone.0045354.g005
Figure 6. Lovastatin induces oxidative stress and autophagy in cancer but not normal cells. Western blot analysis of autophagy marker
LC3B-II and oxidative stress marker HO-1 in normal (SDM104) cells (A) and cancer (ZL55) cells (B) after treatment with CDDP in the presence or
absence of lovastatin are shown. b-Actin were used as loading control. For CDDP treatment, cells were cultured in the presence of 8 mM CDDP for 16
hours; for lovastatin, cells were cultured in the presence of 2mM lovastatin for 24 hours; for the combination of CDDP and lovastatin, 8 mM CDDP were
added 8 hours after 2 mM lovastatin pre-incubation, then cells were cultured for another 16 hours in the presence of CDDP and lovastatin together.
doi:10.1371/journal.pone.0045354.g006
Effects of Lovastatin in Normal and Cancer Cells
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(Figure 6B). However, LC3B-II was not up-regulated in lovastatin-
treated normal cells (Figure 6A). Lovastatin also induced oxidative
stress indicated by the expression of heme oxygenase-1 (HO-1)
[27] in cancer cells (Figure 6B), which was not detected in normal
SDM104 cells either (Figure 6A). Therefore, lovastatin induces
autophagy and oxidative stress in cancer but not normal cells.
Discussion
Side effects of anticancer drugs impair patients’ life quality and
affect therapeutic efficacy [28]. We identified lovastatin from a
screen for agents which reduced cisplatin-induced toxicity in
normal cells, while allowing cancer cells to be killed. Lovastatin
not only mediated the CDDP protective effect for normal cells, but
also induced DNA damage, oxidative stress and autophagy
specifically in cancer cells.
The protection of normal cells against CDDP is in agreement
with the previous observations that lovastatin protected human
endothelial cells (HUVEC) from the toxic effects of anticancer
drugs doxorubicin and etoposide and the killing of ionizing
radiation in vitro [29,30]. Lovastatin also reduced ionizing
radiation-induced normal tissue damage and protected against
anthracycline-induced cardiac toxicity in vivo [31,32].
We showed that lovastatin mediated CDDP protective effect in
normal cells at a concentration of 2 mM, which is in the range of
the pharmacologically attainable serum concentration of lovastatin
(2.361.27 mM) [18], meaning immediate feasibility of clinical
implementation of lovastatin treatment of cancer patients receiv-
ing this drug. Similar concentration had been used for the
protection of mouse CHO cells from doxorubicin, and the
inhibition of geranylgeranylation was suggested to be involved in
the protective effect [33]. We showed here that a similar
mechanism also functions in the lovastatin-mediated protection
of normal human cells from CDDP. We further confirmed that the
protective effect of lovastatin is mainly due to a geranylgeranyla-
tion-dependent mechanism since GGTI but not FTI showed a
similar effect as lovastatin in protecting normal human cells from
CDDP toxicity.
Geranylgeranylated proteins are involved in the control of cell
proliferation [9]. The reduction of this post-translational modifi-
cation may be responsible for the cell proliferation arrest observed
in normal cells after treatment with lovastatin. It is known that
processing of CDDP-DNA-adducts in replicating cells leads to
DNA damage [19,34]. Therefore, replication-quiescent or -
inhibited cells become resistant to CDDP. This may also explain
why lovastatin does not protect cancer cells, where the prolifer-
ation-inhibitory effects of lovastatin may be antagonized by
oncogenic mutations [35].
Recent studies have renewed the therapeutic interest for the
inhibitors of cholesterol biosynthetic pathway in breast cancers
with p53 mutations since they become highly reliant on this
pathway [36]. In two of tested cancer cell lines (ZL55 and MCF-7)
we observed a significant decrease of cell proliferation after
treatment with lovastatin, indicating that even p53-proficient
tumors may be sensitive to some extent to growth inhibitory effects
of lovastatin therapy. In contrast to normal cells, where the effect
on proliferation resulted from the inhibition of DNA replication,
the lovastatin-mediated decrease of cell proliferation in cancer cells
may be attributed to DNA damage-dependent G0/G1 arrest. Due
to the minor decrease in S-phase cells, cancer cells were not
protected by lovastatin from the cytotoxic effect of CDDP.
It is known that lovastatin suppresses proliferation, and induced
oxidative stress, autophagy and apoptosis in cancer cells in vitro
[24,37–45]. In line with these observations, lovastatin inhibited
tumor growth [25] and potentiated the antitumor activity of
doxorubicin and CDDP in vivo [46,47] and long-term use of statin
is associated with lower risk of many cancers [48,49]. Here, we
further show that those lovastatin-induced detrimental effects
happen specifically in cancer but not normal cells.
Therefore, our data demonstrate that lovastatin has a potential
for protecting normal cells from CDDP toxicity without decreasing
the sensitivity of cancer cells to CDDP-based therapy thereby
improving the therapeutic index.
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